



APPENDIX A
PENDING CLAIMS

1. A homoconjugate of two or more monoclonal antibodies, wherein the homoconjugate comprises a monoclonal antibody that does not comprise an Fc region.
2. The homoconjugate of claim 1, wherein no monoclonal antibody comprised in the homoconjugate comprises an Fc region.
3. The homoconjugate of claim 1, wherein the homoconjugate comprises a monoclonal antibody that has anti-neoplastic activity in a conjugated form.
4. The homoconjugate of claim 3, wherein the homoconjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti- α Her2 monoclonal antibody.
5. The homoconjugate of claim 3, wherein the homoconjugate comprises an anti-Her2 monoclonal antibody.
6. The homoconjugate of claim 1, wherein the homoconjugate comprises a monoclonal antibody that has substantially no anti-neoplastic activity in an unconjugated form.
7. The homoconjugate of claim 1, further defined as a homodimer.
8. The homoconjugate of claim 1, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.
9. The homoconjugate of claim 8, wherein the IgG is a mammalian IgG.
10. [Cancelled]

11. A method of making a homoconjugate of two or more monoclonal antibodies, wherein the homoconjugate comprises a monoclonal antibody that does not comprise an Fc region, comprising:

obtaining a first monoclonal antibody that does not comprise an Fc region;
obtaining a second monoclonal antibody; and
conjugating the first monoclonal antibody to the second monoclonal antibody.

12. The method of claim 11, wherein no monoclonal antibody comprised in the homoconjugate comprises an Fc region.

13. The method of claim 11, wherein the first monoclonal antibody is a monoclonal antibody that has anti-neoplastic activity in a conjugated form.

14. The method of claim 11, wherein the second monoclonal antibody is a monoclonal antibody that has anti-neoplastic activity in a conjugated form.

15. The method of claim 11, wherein both the first monoclonal antibody and the second monoclonal antibody are monoclonal antibodies that have anti-neoplastic activity in a conjugated form.

16. The method of claim 14, wherein the monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti- α Her2 monoclonal antibody.

17. The method of claim 14, wherein the monoclonal antibody is an anti-Her2 monoclonal antibody.

18. The method of claim 11, wherein the first monoclonal antibody is a monoclonal antibody that has substantially no anti-neoplastic activity in an unconjugated form.

19. The method of claim 11, wherein the second monoclonal antibody is a monoclonal antibody that has substantially no anti-neoplastic activity in an unconjugated form.
20. The method of claim 11, wherein both the first monoclonal antibody and the second monoclonal antibody are monoclonal antibodies that have substantially no anti-neoplastic activity in an unconjugated form.
21. The method of claim 11, wherein the homoconjugate is further defined as a homodimer.
22. The method of claim 11, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.
23. The method of claim 11, wherein the homoconjugate comprises a mammalian monoclonal antibody.
24. [Cancelled]
25. The method of claim 11, further consisting of:
 - obtaining a third monoclonal antibody; and
 - conjugating the third monoclonal antibody to the homoconjugate.
43. A pharmaceutical composition comprising a homoconjugate comprising a monoclonal antibody and a pharmaceutically acceptable carrier.
44. The pharmaceutical composition of claim 43, wherein no monoclonal antibody comprised in the homoconjugate comprises an Fc region.
45. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a monoclonal antibody that has anti-neoplastic activity in a conjugated form.

46. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti- α Her2 monoclonal antibody.

47. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti- α Her2 monoclonal antibody.

48. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is a monoclonal antibody that has substantially no anti-neoplastic activity in an unconjugated form.

49. The pharmaceutical composition of claim 43, wherein the homoconjugate is further defined as a homodimer.

50. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.

51. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a mammalian monoclonal antibody.

52. [Cancelled]